OncoMatch/Clinical Trials/NCT05295212
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
Is NCT05295212 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Atezolizumab for non small cell lung cancer.
Treatment: Atezolizumab — This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Excluded: EGFR mutation
if they test positive for EGFR ... they are considered as exclusion criteria; if they are adenocarcinoma, they must undergo genetic testing containing at least EGFR, ALK and ROS1
Excluded: ALK fusion
if they test positive for ... ALK ... they are considered as exclusion criteria; if they are adenocarcinoma, they must undergo genetic testing containing at least EGFR, ALK and ROS1
Excluded: ROS1 fusion
if they test positive for ... ROS1, they are considered as exclusion criteria; if they are adenocarcinoma, they must undergo genetic testing containing at least EGFR, ALK and ROS1
Disease stage
Required: Stage II, IIIA, IIIB (N2) (AJCC stage VIII)
Excluded: Stage IIIC
resectable stage II, IIIA, IIIB (N2) (AJCC stage VIII) NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Early stage NSCLC previously treated with systemic anticancer therapy, including treatment with investigational agents
Cannot have received: PD-1/PD-L1 inhibitor or other T cell receptor targeting drug
Previous treatment with PD-1/PD-L1 drugs or treatment with another drug targeting T cell receptor (such as CTLA-4, OX-40, etc.)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1500/μl; platelets ≥ 100,000/μl; hemoglobin ≥ 9.0 g/dl or ≥ 5.6 mmol/l
Kidney function
serum creatinine ≤ 1.5 times uln or calculated creatinine clearance (crcl) ≥ 60 ml/min (using the cock-gault formula)
Liver function
total bilirubin ≤ 1.5 × uln or for subjects with total bilirubin levels > 1.5 × uln, direct bilirubin is within normal limits; ast (sgot) and alt (sgpt) ≤ 2.5 × uln
Cardiac function
baseline ecg showed no pr interval prolongation or atrioventricular block
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify